Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Safety Board To Meet Every Six Weeks

This article was originally published in The Pink Sheet Daily

Executive Summary

The board discussed FDA's recent action on fentanyl transdermal patches (J&J's Duragesic and generics) and Purdue's Palladone (hydromorphone extended-release) during a July 27 meeting, FDA's meeting summary says.

You may also be interested in...



FDA Drug Safety Oversight Board Should Have More Independent Outside Advisors, Cmte. Says

Board Executive Director Susan Cummins maintains that as a "management tool," the DSOB must run in a different way from a public advisory committee.

FDA Drug Safety Oversight Board Should Have More Independent Outside Advisors, Cmte. Says

Board Executive Director Susan Cummins maintains that as a "management tool," the DSOB must run in a different way from a public advisory committee.

FDA Public Meeting On Drug Safety Communication Set For Dec. 7-8

Agency seeks public input on effectiveness of currently used risk communication tools; meeting is part of ongoing drug safety initiative.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel